Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Charles Stiefel

Charles Stiefel Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Charles Stiefel News

American Skin Association Announces Daneen & Charles Stiefel Investigative Scientist Awards

Apr 18, 2018

Share this article NEW YORK, April 17, 2018 /PRNewswire-USNewswire/ -- On April 10, at their Annual Spring Gala at The Plaza Hotel, American Skin Association (ASA) announced the Daneen & Charles Stiefel Investigative Scientist Awards. The Stiefel Family, longtime supporters of ASA, has generously contributed $300,000 to support grants for melanoma research. The purpose of this funding mechanism is to identify and support emerging leaders in dermatology focused on melanoma research. Recent changes at the NIH have limited support for mid-career investigators, instead favoring on the work of senior and early-career investigators. The grants funded by the Stiefel family will offer much needed support to mid-career investigators poised to become leaders in key areas of melanoma research. Candidates must have an MD and/or PhD, with a substantial track record in their melanoma research area. "We are so grateful to Daneen and Charles Stiefel for their overwhelming generosity," said Howard P. Milstein, Chairman of ASA. "Their tremendous compassion for those suffering from devastating diseases is an inspiration to us all. For decades, the Stiefel family has generously funded crucial studies and provided hope to those desperately awaiting cures for skin cancer and other skin diseases. ASA applauds their continuing support of our organization's mission and our common goal." At last night's gala, the first two Daneen & Charles Stiefel Investigative Scientist Award recipients were announced and lauded for their achievements in the field of melanoma research: Neil Box, PhD, Associate Professor within the Departments of Dermatology and Epidemiology at the University of Colorado Anschutz Medical Campus, is an emerging leader in the study of melanoma risk. He has made important contributions to the understanding of melanoma risk mediated via genetic factors and environmental exposures. Dr. Box is dedicated to educating a new generation of melanoma investigators. Deborah Lang, PhD, Associate Professor of Dermatology at Boston University, is committed to educating the next generation of melanoma researchers. Dr. Lang leads a lab focused on the molecular biology of melanoma. Her cancer research and findings related to melanocyte stem cells have had broad impact, with discoveries into the molecular mechanisms of melanoma revealing potential "Achille's heel" factors that, if targeted and inhibited therapeutically, would lead to catastrophic consequences to the cancer cells. These findings may provide next generation treatment options for cancer patients. A philanthropist and pharma icon, Charles Stiefel is Chairman of Brickell Biotech, Inc. With more than 36 years of experience in the pharmaceutical industry and tremendous compassion for those suffering from devastating diseases, Stiefel has spent decades generously supporting ASA and countless others causes. Daneen and Charles Stiefel's gifts have funded crucial studies and provided hope to those suffering from skin cancer and other skin diseases, while providing immense contributions to the field of dermatology and other medical fields. ABOUT AMERICAN SKIN ASSOCIATION A unique collaboration of patients, families, advocates, physicians and scientists, ASA has evolved over thirty-one years as a leading force in efforts to defeat melanoma, skin cancer and diseases. Established to serve the now more than 100 million Americans – one third of the U.S. population – afflicted with skin disorders, the organization's mission remains to: advance research, champion skin health – particularly among children, and drive public awareness about skin disease. For more information, visit americanskin.org.

Charles Stiefel Investments

1 Investments

Charles Stiefel has made 1 investments. Their latest investment was in Brickell Biotech as part of their Series C on February 2, 2015.

CBI Logo

Charles Stiefel Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/3/2015

Series C

Brickell Biotech

$10M

Yes

2

Date

2/3/2015

Round

Series C

Company

Brickell Biotech

Amount

$10M

New?

Yes

Co-Investors

Sources

2

Charles Stiefel Portfolio Exits

1 Portfolio Exit

Charles Stiefel has 1 portfolio exit. Their latest portfolio exit was Brickell Biotech on June 03, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/3/2019

Reverse Merger

$99M

5

Date

6/3/2019

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

5

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.